BAG956 inhibits proliferation of human leukemia cells. (A) BAG956 treatment (3-day) of Ba/F3, CCRF-CEM, Jurkat, THP-1, BV-173, KU812, MEG-01.(B) BAG956 treatment (4-day) of C1498, SUP-B15, KG-1, GDM-1. (C)BAG956 treatment (3-day) of Ba/F3 and Ba/F3.p210. (D) BAG956 treatment of primary AML patient bone marrow cells after 24 hours of treatment. (E) Left panel: Colony assay investigating effect of BAG956 on normal human bone marrow. Right panel: Colony assay investigating effect of BAG956 on primary murine bone marrow cells. (F) Colony assay investigating effect of BAG956 on primary AML patient bone marrow cells.